Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clarithromycin

FDA-approved product (tablet, oral), marketed as Biaxin, Biaxin Xl, Clarithromycin.

Registered studies
50+
Lab records
25
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Clarithromycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Chronic bronchitis
  • Duodenal ulcer
  • Infection
  • Maxillary sinusitis
  • Otitis media
  • Pharyngitis
  • Pneumonia
  • Recurrent tonsillitis
  • Sinusitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Macrolides
FDA pharmacologic class
Macrolide Antimicrobial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01FA09

Repurposing investigation

Clarithromycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA66.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli63.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae75.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis75.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 10 of 12 lab records
  • E. coli: measured active in 2 of 4 lab records
  • K. pneumoniae: measured active in 7 of 7 lab records
  • M. tuberculosis: measured active in 1 of 2 lab records
Open Clarithromycin in ChEMBL Registered studies below
Show the 25 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clarithromycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clarithromycin Mechanisms in Hypersomnia Syndromes

    NCT04026958 · start 2019-09-04

    Registered record
    Registry ID
    NCT04026958
    Conditions
    Narcolepsy Without Cataplexy; Idiopathic Hypersomnia; Narcolepsy With Cataplexy
    Interventions
    Clarithromycin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-09-04
    Completion
    2025-06-18
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNarcolepsy Without Cataplexy; Idiopathic Hypersomnia; Narcolepsy With Cataplexy
    InterventionClarithromycin; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Empirical vs Tailored Therapy for H. Pylori Infection

    NCT04006340 · start 2019-01-04

    Registered record
    Registry ID
    NCT04006340
    Conditions
    Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation; Helicobacter Pylori Infection
    Interventions
    triple therapy; quadruple therapy; dual-priming oligonucleotide-based multiplex (DPO)-PCR test
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-01-04
    Completion
    2019-08-31
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation; Helicobacter Pylori Infection
    Interventiontriple therapy; quadruple therapy; dual-priming oligonucleotide-based multiplex (DPO)-PCR test
    PhaseNot applicable
    Registry statusUnknown

  • Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication

    NCT03802318 · start 2019-01-02

    Registered record
    Registry ID
    NCT03802318
    Conditions
    Helicobacter Pylori Infection; Helicobacter Gastritis; Helicobacter-Associated Pyloric Ulcer
    Interventions
    Rabeprazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-01-02
    Completion
    2020-12
    Enrolment
    530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Helicobacter Gastritis; Helicobacter-Associated Pyloric Ulcer
    InterventionRabeprazole
    PhaseNot applicable
    Registry statusUnknown

  • Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection

    NCT03565484 · start 2019-01-01

    Registered record
    Registry ID
    NCT03565484
    Conditions
    Helicobacter Pylori Infection
    Interventions
    susceptibility guided therapy; personal medication history guided therapy; salvage treatment for failed eradication
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-01-01
    Completion
    2020-06-30
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionsusceptibility guided therapy; personal medication history guided therapy; salvage treatment for failed eradication
    PhasePhase 4
    Registry statusUnknown

  • Probiotics in the Reduction of Adverse Effects and Dysbiosis of H. Pylori Eradication

    NCT03722433 · start 2018-08-29

    Registered record
    Registry ID
    NCT03722433
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Vigiis 101-LAB and sequential therapy; Placebo and sequential therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-08-29
    Completion
    2020-07-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionVigiis 101-LAB and sequential therapy; Placebo and sequential therapy
    PhasePhase 4
    Registry statusUnknown

  • ADDITION OF BISMUTH TO THE STANDARD TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION

    NCT03968302 · start 2018-06-01

    Registered record
    Registry ID
    NCT03968302
    Conditions
    Helicobacter Pylori Infection
    Interventions
    ARM A Triple therapy for helicobacter pylori; ARM B Quadruple therapy for helicobacter pylori
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-06-01
    Completion
    2019-05-15
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionARM A Triple therapy for helicobacter pylori; ARM B Quadruple therapy for helicobacter pylori
    PhasePhase 2
    Registry statusCompleted

  • S. Aureus Decolonization in HPN Patients.

    NCT03173053 · start 2018-02-08

    Registered record
    Registry ID
    NCT03173053
    Conditions
    Staphylococcus Aureus; Motility Disorder
    Interventions
    Doxycycline; Trimethoprim; Sulfamethoxazole/trimethoprim; Clindamycin; Clarithromycin; Ciprofloxacin; Fusidic Acid; Rifampin; Chlorhexidine; Mupirocin; Betadine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2018-02-08
    Completion
    2021-10-14
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus; Motility Disorder
    InterventionDoxycycline; Trimethoprim; Sulfamethoxazole/trimethoprim; Clindamycin +7 more
    PhaseNot applicable
    Registry statusTerminated

  • Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System

    NCT03345992 · start 2017-12-15

    Registered record
    Registry ID
    NCT03345992
    Conditions
    Sepsis; Pneumonia; Gram-Negative Bacteria Infection; Multiple Organ Failure; Respiratory Distress Syndrome; Mortality; Biomarkers
    Interventions
    Clarithromycin; Water for injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-12-15
    Completion
    2020-12-19
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis; Pneumonia; Gram-Negative Bacteria Infection; Multiple Organ Failure +3 more
    InterventionClarithromycin; Water for injection
    PhasePhase 3
    Registry statusCompleted

  • Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

    NCT04287660 · start 2017-10-19

    Registered record
    Registry ID
    NCT04287660
    Conditions
    Multiple Myeloma
    Interventions
    clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-10-19
    Completion
    2025-01-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    Interventionclarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
    PhasePhase 3
    Registry statusUnknown

  • H. Pylori Eradication for Moderate ITP

    NCT03177629 · start 2017-05-23

    Registered record
    Registry ID
    NCT03177629
    Conditions
    Immune Thrombocytopenic Purpura; Helicobacter Pylori; Immune Thrombocytopenia
    Interventions
    treatment : H. pylori eradication
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-05-23
    Completion
    2020-12
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmune Thrombocytopenic Purpura; Helicobacter Pylori; Immune Thrombocytopenia
    Interventiontreatment : H. pylori eradication
    PhasePhase 3
    Registry statusUnknown

  • Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment

    NCT02988089 · start 2017-04-20

    Registered record
    Registry ID
    NCT02988089
    Conditions
    Helicobacter Pylori Infection; Antimicrobial Susceptibility Testing
    Interventions
    Clarithromycin susceptibility dependant strategy; 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline ); proton pump inhibitor (PPI) and Colloidal Bismuth Pectin; amoxicillin and clarithromycin or amoxicillin and furazolidone; amoxicillin and furazolidone or amoxicillin and tetracycline; amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-04-20
    Completion
    2017-09
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Antimicrobial Susceptibility Testing
    InterventionClarithromycin susceptibility dependant strategy; 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline ); proton pump inhibitor (PPI) and Colloidal Bismuth Pectin; amoxicillin and clarithromycin or amoxicillin and furazolidone +2 more
    PhasePhase 4
    Registry statusUnknown

  • Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

    NCT03043989 · start 2017-03-21

    Registered record
    Registry ID
    NCT03043989
    Conditions
    Prostate Cancer
    Interventions
    Docetaxel; Cabazitaxel; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2017-03-21
    Completion
    2019-07-26
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDocetaxel; Cabazitaxel; Clarithromycin
    PhasePhase 1
    Registry statusTerminated

  • Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

    NCT02986451 · start 2016-12

    Registered record
    Registry ID
    NCT02986451
    Conditions
    Relapse/Refractory Multiple Myeloma
    Interventions
    clarithromycin; Lenalidomide; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2016-12
    Completion
    2019-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapse/Refractory Multiple Myeloma
    Interventionclarithromycin; Lenalidomide; Dexamethasone
    PhasePhase 2
    Registry statusWithdrawn

  • Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole

    NCT02998437 · start 2016-12

    Registered record
    Registry ID
    NCT02998437
    Conditions
    Drug Interaction Potentiation
    Interventions
    Ilaprazole 10mg; Clarithromycin 500mg; Amoxicillin 500 Mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-12
    Completion
    2017-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interaction Potentiation
    InterventionIlaprazole 10mg; Clarithromycin 500mg; Amoxicillin 500 Mg
    PhasePhase 1
    Registry statusCompleted

  • Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication

    NCT02934152 · start 2016-10

    Registered record
    Registry ID
    NCT02934152
    Conditions
    Gastroesophageal Reflux Disease
    Interventions
    H pylori eradication; H pylori eradication timing
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-10
    Completion
    2019-09
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux Disease
    InterventionH pylori eradication; H pylori eradication timing
    PhasePhase 4
    Registry statusUnknown